Shareholders Lose Trust in CEO and Board's Value Creation

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: Apr 29 2026

0mins

SEER-0.59%

Should l Buy SEER?

Source: Yahoo Finance

Trust Crisis: The Radoff-JEC Group highlights that Seer's Board has failed to achieve any growth over the past five years, leading to a significant loss of trust among shareholders in CEO Omid Farokhzad and the incumbent Board's ability to create future value.
Acquisition Proposal Rejected: The Radoff-JEC Group's proposal to acquire Seer for $2.35 per share, offering a 39% premium, was rejected by the Board, indicating a failure to act in the best interests of all shareholders and exacerbating shareholder dissatisfaction.
Poor Financial Performance: Under Farokhzad's leadership, Seer's stock price has declined over 90% since its IPO, with cumulative losses exceeding $465 million and virtually no revenue growth, illustrating the company's ongoing financial distress under his management.
Commitment to Accountability: The Radoff-JEC Group pledges to elect three independent directors at the upcoming annual meeting to rebuild Seer's value and oversee a credible strategic review process, aiming to serve the interests of all shareholders.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy SEER?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on SEER

About SEER

Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Seer Acquisition Offer Raised to $2.40 per Share

5 days agoseekingalpha

Acquisition Proposal Increase: Investors Bradley Radoff and Michael Torok have raised their acquisition offer for Seer to $2.40 per share in cash, plus a contingent value right tied to future asset sales, indicating recognition of the company's value.
Significant Premium: This proposal represents a 42% premium over Seer's unaffected share price from April 10, reflecting investor confidence in the company's potential value and possibly prompting management to reconsider its strategic direction.
Investor Ownership Stake: The investor group currently owns about 7.8% of Seer and has criticized the company's poor operating performance, urging the board to take this proposal seriously, highlighting shareholder concerns regarding corporate governance.
Disappointing Earnings Outlook: Seer's Q1 2026 earnings report revealed a GAAP EPS of -$0.30 and revenue of $2.8 million, both missing market expectations, which further exacerbates investor concerns about the company's future growth prospects.

Seer, Inc. Q1 2026 Earnings Call Insights

6 days agoseekingalpha

Weak Revenue Performance: Seer reported total revenue of $2.8 million for Q1 2026, a 33% decline from $4.2 million in Q1 2025, reflecting ongoing depressed academic funding and increased competitive pressures that pose significant market challenges.
Strategic Adjustments: The company appointed a new Chief Commercial Officer to drive sales momentum and filed a patent infringement lawsuit against Nanomix Biotechnology, demonstrating Seer's commitment to protecting its intellectual property and enhancing its competitive position in the market.
Severe Financial Condition: The net loss for Q1 was $16.8 million with operating expenses reaching $18.2 million; despite repurchasing shares worth $24.5 million, the free cash flow remained negative at $15.7 million, indicating tight liquidity.
Outlook Reaffirmation: Despite a weak start, Seer reaffirmed its full-year revenue guidance of $16 million to $18 million for 2026, with management expressing optimism about a rebound in the second half of the year as customer reorder dynamics are expected to improve.

Seer Files Patent Infringement Lawsuit Against Nanomics

6 days agoseekingalpha

Patent Infringement Lawsuit: Seer (SEER) announced on Wednesday that it has filed a patent infringement lawsuit against Nanomics Biotechnology, alleging infringement of five U.S. patents related to nanoparticle protein enrichment technology, demonstrating Seer's commitment to protecting its intellectual property.
Collaboration Involvement: Brigham and Women’s Hospital has joined the lawsuit, indicating the complexity and significance of the case, which could have a substantial impact on Seer's market position regarding its Proteograph product suite.
Seeking Damages: Seer is pursuing monetary damages and injunctive relief in the lawsuit, reflecting its strong opposition to Nanomics' alleged infringement through its Proteonano kits and workstations, which may affect Nanomics' business operations.
Commitment to Technology Protection: CEO Omid Farokhzad stated that the company would aggressively defend its proteomics technology portfolio, highlighting Seer's emphasis on its technology and determination in future market competition.

SEER INC: CANACCORD GENUITY BEGINS COVERAGE WITH A BUY RATING AND A TARGET PRICE OF $4

May 05 2026moomoo

Company Overview: SEER Inc. is a company that focuses on providing innovative solutions in the field of genetic analysis and diagnostics.
Recent Developments: The company has received a buy rating from analysts, indicating positive expectations for its future performance.
Market Position: SEER Inc. is positioned within the biotechnology sector, which is experiencing significant growth and interest from investors.
Target Price: Analysts have set a target price of $4 for SEER Inc., suggesting potential for appreciation in its stock value.

Latest Wall Street Rating Updates

May 04 2026CNBC

Apple Rating Reaffirmed: Bernstein raised Apple's price target from $340 to $350, anticipating a 17% revenue growth in FQ2 and a guidance of 14-17% for FQ3, with gross margins at 49.3%, indicating strong market performance and future growth potential.
KE Holdings Upgrade: Goldman Sachs upgraded KE Holdings from neutral to buy, believing the recent stock price pullback provides an attractive re-entry point for investors, reflecting confidence in the Chinese real estate market.
Palantir and AMD Downgrade: HSBC downgraded Palantir from buy to hold due to increasing competition; it also downgraded AMD, citing significant stock price appreciation and limited future earnings upside.
Packaging Corp Upgraded to Buy: Deutsche Bank upgraded Packaging Corp from hold to buy, raising the price target to $256 based on strong Q1 performance and positive management outlook, indicating a pivotal moment for the company in the packaging industry.